ZDHHC18 and ovarian carcinoma: Pei et al. found that a higher level of ZDHHC18 mRNA expression was associated with poorer survival in patients with ovarian cancer and malate dehydrogenase 2 (MDH2) palmitoylation, catalyzed by ZDHHC18, promoted the malignant progression of ovarian cancer [59].